Nuzenio

Alteogen Licenses Subcutaneous

Alteogen Licenses Subcutaneous news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 8 publisher sources 100/100 entity strength

Latest news

Alteogen signs up to $365 million licensing deal for Hybrozyme drug delivery technology - Indian Pharma PostIndian Pharma Post · Fri, 07 Aug 2026 02:36:49 GMTAlteogen signs $365m Hybrozyme licensing deal with pharma company - Pharmaceutical Business review -Pharmaceutical Business review - · Thu, 06 Aug 2026 17:25:31 GMTAlteogen Licenses Subcutaneous Platform to Undisclosed Global Pharma Company in Deal Worth Up to $365 Million - biopharminternational.combiopharminternational.com · Wed, 05 Aug 2026 19:10:58 GMTAlteogen Inks Licensing Pact with Global Pharma Company to Develop, Commercialize Subcutaneous Biologic - Contract PharmaContract Pharma · Wed, 05 Aug 2026 15:57:30 GMTAlteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product - finance.yahoo.comfinance.yahoo.com · Wed, 05 Aug 2026 12:00:00 GMTAlteogen inks up to $365 mil. licensing deal with global pharma for SC biologic - koreabiomed.comkoreabiomed.com · Wed, 05 Aug 2026 00:45:29 GMTAlteogen licenses SC platform to global pharma in $365 million deal - CHOSUNBIZ - ChosunbizChosunbiz · Tue, 04 Aug 2026 23:37:00 GMTAlteogen Signs New $365 Million Technology Out-Licensing Deal... "Aiming for Multiple Product Agreements in the Second Half" - asiae.co.krasiae.co.kr · Tue, 04 Aug 2026 23:17:40 GMT

Timeline

Fri, 07 Aug 2026 02:36:49 GMTAlteogen signs up to $365 million licensing deal for Hybrozyme drug delivery technology - Indian Pharma Post
Thu, 06 Aug 2026 17:25:31 GMTAlteogen signs $365m Hybrozyme licensing deal with pharma company - Pharmaceutical Business review -
Wed, 05 Aug 2026 19:10:58 GMTAlteogen Licenses Subcutaneous Platform to Undisclosed Global Pharma Company in Deal Worth Up to $365 Million - biopharminternational.com
Wed, 05 Aug 2026 15:57:30 GMTAlteogen Inks Licensing Pact with Global Pharma Company to Develop, Commercialize Subcutaneous Biologic - Contract Pharma
Wed, 05 Aug 2026 12:00:00 GMTAlteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product - finance.yahoo.com
Wed, 05 Aug 2026 00:45:29 GMTAlteogen inks up to $365 mil. licensing deal with global pharma for SC biologic - koreabiomed.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Alteogen Licenses Subcutaneous.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.